-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Latest From Biotech Now
Inside Health Policy: Clearing Up Confusion About Bills Updating Vaccine Tax Code
Inside Health Policy’s Alaina Busch wrote a story today on confusion that has been spreading recently related to vaccines excise legislation. Vaccines protect people from seasonal flu, and new strains have recently been approved to further protect public health. As such, the vaccine excise tax must in turn be updated to include recent approvals. S. 391 and H.R. 475 update the existing excise tax to cover the newest seasonal influenza vaccines. The legislation does not Read More >
What OxyContin Tells Us About the Value of “Evergreening” and Patents
A few weeks ago, the FDA announced that they would not allow generic versions of older versions of OxyContin. The original formulation of OxyContin goes off patent today. The original formulation did not have “tamper-resistant qualities” that prevent people from “crushing, breaking, and dissolution using a variety of tools and solvents.” The article reports that the decision will keep Teva Pharmaceuticals and Impax Laboratories from making the older version which the FDA has determined is too dangerous Read More >
Biopharmaceuticals and Accountable Care Organizations: Balancing Cost and Quality
As biopharmaceutical manufacturers consider the new reality of accountable care organizations (ACOs) and the impact on their businesses, they must be ready to demonstrate the value of their products in ways that recognize the fine balance of cost and quality that ACO and ACO-like models seek to achieve. According to panelists speaking at the 2013 BIO International Convention session entitled, “Accountable Care Organization (ACO) Framework for Biopharmaceuticals,” there are three primary considerations when it comes Read More >
BioGENEius – From Student Participant to Judge
It’s been two years since I participated as a student in BioGENEius. Last year I presented my work at the White House Science Fair and now I am privileged to attend BioGENEius 2013 as a judge. BioGENEius 2013 is in Chicago this year and as a student at Northwestern University in nearby Evanston, I jumped at the chance to attend again. As I joined the judges and learned about their backgrounds, I felt honored to Read More >
How to Drive International Innovation: Scientific American Worldview
Which countries are winning the innovation game? Will the U.S. maintain its leadership position in the future? Have emerging markets lived up to the hype? Which new partnerships are transforming industries? For the fifth year, Scientific American (SA) released their Worldview: A Global Biotechnology Perspective report at the 2013 BIO International Convention in Chicago. Included in this year’s report is the longest list of country rankings that SA has ever compiled and the numbers reveal Read More >
